Hyman Charles D Sells 1,092 Shares of Pfizer Inc. (NYSE:PFE)

Hyman Charles D decreased its holdings in shares of Pfizer Inc. (NYSE:PFE) by 0.7% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 151,886 shares of the biopharmaceutical company’s stock after selling 1,092 shares during the quarter. Hyman Charles D’s holdings in Pfizer were worth $4,373,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of the business. BluePath Capital Management LLC purchased a new stake in Pfizer in the 3rd quarter valued at about $45,000. Oak Asset Management LLC increased its holdings in Pfizer by 29.7% during the 3rd quarter. Oak Asset Management LLC now owns 20,976 shares of the biopharmaceutical company’s stock worth $696,000 after purchasing an additional 4,800 shares during the period. DMC Group LLC lifted its holdings in shares of Pfizer by 3.7% in the 3rd quarter. DMC Group LLC now owns 23,939 shares of the biopharmaceutical company’s stock worth $794,000 after buying an additional 864 shares during the period. IFM Investors Pty Ltd raised its holdings in shares of Pfizer by 3.2% in the third quarter. IFM Investors Pty Ltd now owns 1,158,162 shares of the biopharmaceutical company’s stock valued at $38,416,000 after acquiring an additional 35,484 shares in the last quarter. Finally, Foyston Gordon & Payne Inc lifted its stake in Pfizer by 13.4% in the third quarter. Foyston Gordon & Payne Inc now owns 68,765 shares of the biopharmaceutical company’s stock worth $2,281,000 after acquiring an additional 8,113 shares during the period. Institutional investors own 68.36% of the company’s stock.

Pfizer Stock Performance

Shares of NYSE PFE traded down $0.39 during midday trading on Tuesday, reaching $27.78. 65,400,901 shares of the stock were exchanged, compared to its average volume of 43,591,664. The company has a quick ratio of 0.69, a current ratio of 0.91 and a debt-to-equity ratio of 0.69. The firm has a 50-day simple moving average of $26.92 and a two-hundred day simple moving average of $28.12. Pfizer Inc. has a twelve month low of $25.20 and a twelve month high of $40.37. The firm has a market cap of $157.28 billion, a price-to-earnings ratio of -462.84, a PEG ratio of 1.17 and a beta of 0.63.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share for the quarter, topping analysts’ consensus estimates of $0.56 by $0.26. The company had revenue of $14.88 billion during the quarter, compared to analysts’ expectations of $13.87 billion. Pfizer had a positive return on equity of 8.58% and a negative net margin of 0.56%. Pfizer’s quarterly revenue was down 19.5% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.23 EPS. As a group, analysts anticipate that Pfizer Inc. will post 2.39 EPS for the current fiscal year.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, June 14th. Stockholders of record on Friday, May 10th will be given a $0.42 dividend. The ex-dividend date is Thursday, May 9th. This represents a $1.68 annualized dividend and a dividend yield of 6.05%. Pfizer’s dividend payout ratio (DPR) is -2,799.53%.

Wall Street Analysts Forecast Growth

Several analysts have commented on PFE shares. Guggenheim assumed coverage on shares of Pfizer in a research report on Friday, February 23rd. They set a “buy” rating and a $36.00 price target for the company. Morgan Stanley increased their price objective on Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a report on Thursday, May 2nd. BMO Capital Markets reaffirmed an “outperform” rating and set a $36.00 target price (up from $33.00) on shares of Pfizer in a research report on Thursday, May 2nd. Cantor Fitzgerald reissued an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a report on Monday, April 15th. Finally, Argus downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Eleven research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $36.00.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.